Kylo 11
Alternative Names: Kylo-11Latest Information Update: 24 May 2024
At a glance
- Originator Kylonova (Xiamen) Biopharma
- Class Small interfering RNA
- Mechanism of Action Small interfering RNA stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 18 Apr 2024 Preclinical trials in Cardiovascular disorders in China (SC)
- 18 Apr 2024 Kylonova (Xiamen) Biopharma plans a phase I trial for Cardiovascular disorders (In volunteers) in China (SC) in May 2024 (NCT06363851)